Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.70
-0.9800-1.45%
Post-market: 66.41-0.2900-0.43%19:30 EDT
Volume:1.59M
Turnover:106.77M
Market Cap:12.89B
PE:176.00
High:68.34
Open:67.55
Low:66.52
Close:67.68
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.90
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.04
PE(LYR):37.06

Loading ...

Zura Bio appoints Muzammil Mustufa chief business officer

Reuters
·
May 13

BioMarin EVP, Chief R&D Officer Gregory R. Friberg disposes 3,281 shares for $176,666.85

Reuters
·
May 12

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 08

Guggenheim Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 06

U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group

Reuters
·
May 06

Stock Track | BioMarin Pharmaceutical Plummets 5.01% Intraday on Lowered Earnings Outlook and Analyst Price Target Cuts

Stock Track
·
May 06

BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says

MT Newswires Live
·
May 06

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

MT Newswires Live
·
May 05

BioMarin price target raised to $120 from $110 at Evercore ISI

TIPRANKS
·
May 05

Morgan Stanley Trims Price Target on BioMarin Pharmaceutical to $119 From $120, Keeps Overweight Rating

MT Newswires Live
·
May 05

BioMarin Pharmaceutical Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Biomarin Pharmaceutical Inc : Morgan Stanley Cuts Target Price to $119.00 From $120.00

THOMSON REUTERS
·
May 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN) and Sanofi (OtherSNYNF)

TIPRANKS
·
May 05

GUIDANCE: (BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.85 - $5.05

MT Newswires Live
·
May 05

BioMarin Q1 revenue rises, beats estimates

Reuters
·
May 05

BioMarin Q1 GAAP net income drops 43% to $106 million; revenue rises 3% to $766 million

Reuters
·
May 05

Biomarin Pharmaceutical Q1 Adj. EPS $0.76 Misses $0.79 Estimate, Sales $766.208M Beat $755.610M Estimate

Benzinga Earnings
·
May 05

Biomarin Pharmaceutical Outlook FY Adjusted EPS USD 4.85-5.05

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 EPS USD 0.54

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 Adjusted EPS USD 0.76 VS. Ibes Estimate USD 0.75

THOMSON REUTERS
·
May 05